

Methods in
Molecular Biology 756

Springer Protocols

Louis M. Luttrell
Stephen S. G. Ferguson *Editors*

Signal Transduction Protocols

Third Edition

 Humana Press

Signal Transduction Protocols

Edited by

Louis M. Luttrell

*Departments of Medicine and Biochemistry & Molecular Biology,
Medical University of South Carolina, Charleston, SC, USA;
Charleston VA Medical Center, Charleston, SC, USA*

Stephen S.G. Ferguson

*The J. Allyn Taylor Centre for Cell Biology, Robarts Research Institute,
The University of Western Ontario, London, ON, Canada;
Department of Physiology & Pharmacology, The University of Western Ontario,
London, ON, Canada*

 **Humana Press**

Editors

Louis M. Luttrell MD, PhD
Departments of Medicine and
Biochemistry & Molecular Biology
Medical University of South Carolina
Charleston, SC, USA
Charleston VA Medical Center, Charleston
SC, USA
luttrell@musc.edu

Stephen S. G. Ferguson PhD
The J. Allyn Taylor Centre for Cell Biology
Robarts Research Institute
The University of Western Ontario
London, ON, Canada
Department of Physiology & Pharmacology
The University of Western Ontario
London, ON, Canada
ferguson@robarts.ca

ISSN 1064-3745 e-ISSN 1940-6029
ISBN 978-1-61779-159-8 e-ISBN 978-1-61779-160-4
DOI 10.1007/978-1-61779-160-4
Springer New York Dordrecht Heidelberg London

Library of Congress Control Number: 2011935994

© Springer Science+Business Media, LLC 2011

All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connection with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden.

The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights.

Printed on acid-free paper

Humana Press is part of Springer Science+Business Media (www.springer.com)

METHODS IN MOLECULAR BIOLOGY™

Series Editor
John M. Walker
School of Life Sciences
University of Hertfordshire
Hatfield, Hertfordshire, AL10 9AB, UK

For further volumes:
<http://www.springer.com/series/7651>

Preface

Signal transduction is the process whereby a physical or chemical stimulus in the extracellular environment is detected by a receptor on the plasma membrane or in the cytosol or nucleus of a sensitive cell and translated into a chemical or electrochemical signal that produces a change in cellular metabolism. Rather than representing a series of simple linear cascades, it is increasingly clear that signal transduction is a highly organized and integrated process. Extensive crosstalk between signaling cascades, communicated directly through receptor oligomerization or indirectly through the activation of autocrine and paracrine feedback loops, enables one type of receptor to modulate activity in multiple intracellular pathways. Additional factors impose spatial or temporal constraints on signaling that influence the final cellular response by determining where within the cell, and for how long, the signal persists.

This volume focuses on experimental approaches to understand the complexity of signal transduction. Introductory chapters have been included to provide perspective on several of the challenges in signal transduction research and guidance on selecting the best approaches to various types of questions. The individual chapters provide detailed experimental protocols, beginning with the effects of ligand binding on receptor conformation and effector coupling, then moving inside the cell to capture the spatial and temporal characteristics of signaling events.

We would like to express our deepest appreciation to the coauthors of this publication. We hope that *Signal Transduction Protocols – Third Edition* will prove to be a valuable resource for future progress in the field of signal transduction research.

Charleston, SC
London, ON

Louis M. Luttrell
Stephen S.G. Ferguson

Contributors

- LAMIA ACHOUR • *Institut Cochin, Université Paris Descartes, Paris, France*
- BENJAMIN AGUILA • *Hormones and Cancer Research Unit, Department of Medicine, McGill University Health Center Research Institute, McGill University, Montréal, QC, Canada*
- SYED M. AHMED • *Department of Pharmaceutical Sciences & Biochemistry, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada*
- CHRISTOPHE ALTIER • *Department of Physiology and Pharmacology, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada*
- STÉPHANE ANGERS • *Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada; Department of Biochemistry, Faculty of Medicine, University of Toronto, Toronto, ON, Canada*
- NICOLAS AUDET • *Department of Pharmacology, Faculty of Medicine, University of Montreal, Montreal, QC, Canada; Centre de Recherche du CHU Ste-Justine, Bureau, Montreal, QC, Canada*
- LARRY S. BARAK • *Department of Cell Biology, Duke University, Durham, NC, USA*
- CATHERINE H. BERLOT • *Weis Center for Research, Geisinger Clinic, Danville, PA, USA*
- BROCK F. BINKOWSKI • *Promega Corporation, Madison, WI, USA*
- WAYNE CHADWICK • *Receptor Pharmacology Unit, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA*
- RAELENE A. CHARBENEAU • *Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI, USA*
- SHENG CHEN • *Department of Neuroscience, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada*
- LAÉTTITIA COMPS-AGRAR • *Institut de Génomique Fonctionnelle, University of Montpellier 1 and 2, Montpellier, France*
- LIANNE B. DALE • *The J. Allyn Taylor Centre for Cell Biology, Robarts Research Institute, The University of Western Ontario, London, ON, Canada; Department of Physiology & Pharmacology, The University of Western Ontario, London, ON, Canada*
- AVAIS M. DAULAT • *Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada*
- CHARLENE DEPRY • *Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA*
- PO HIEN EAR • *Département de Biochimie, Université de Montréal, Montréal, QC, Canada*
- ERIC TRINQUET • *Cisbio Bioassays, Bagnols-sur-Cèze Cedex, France*
- FRANK FAN • *Promega Corporation, Madison, WI, USA*

- STEPHEN S.G. FERGUSON • *The J. Allyn Taylor Centre for Cell Biology, Robarts Research Institute, The University of Western Ontario, London, ON, Canada; Department of Physiology & Pharmacology, The University of Western Ontario, London, ON, Canada*
- LISA L. GALLEGOS • *Department of Pharmacology, University of California San Diego, La Jolla, CA, USA*
- RANDY A. HALL • *Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA*
- TERENCE E. HÉBERT • *Department of Pharmacology and Therapeutics, McGill University, Montréal, QC, Canada*
- THOMAS R. HYNES • *Weis Center for Research, Geisinger Clinic, Danville, PA, USA*
- RALF JOCKERS • *Institut Cochin, Université Paris Descartes, Paris, France*
- MAUD KAMAL • *Institut Cochin, Université Paris Descartes, Paris, France*
- KULJEET KAUR • *Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI, USA*
- JASON M. KEHRL • *Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, MI, USA*
- TERRY P. KENAKIN • *Department of Pharmacology, University of North Carolina, School of Medicine, Chapel Hill, NC, USA*
- JANE E. LAMERDIN • *Odyssey Thera Incorporated, San Ramon, CA, USA*
- CHRISTIAN LANDRY • *Département de Biochimie, Université de Montréal, Montréal, QC, Canada*
- STÉPHANE A. LAPORTE • *Hormones and Cancer Research Unit, Departments of Medicine and Pharmacology and Therapeutics, McGill University Health Center Research Institute, McGill University, Montréal, QC, Canada*
- SHUPENG LI • *Department of Neuroscience, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada*
- FANG LIU • *Departments of Neuroscience and Psychiatry, Centre for Addiction and Mental Health, University of Toronto, Toronto, ON, Canada*
- LOUIS M. LUTTRELL • *Departments of Medicine and Biochemistry & Molecular Biology, Medical University of South Carolina, Charleston, SC, USA; Charleston VA Medical Center, Charleston, SC, USA*
- MOHAN K. MALLESHAIAH • *Département de Biochimie, Université de Montréal, Montréal, QC, Canada*
- BRONWEN MARTIN • *Metabolism Unit, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA*
- STEFANO MARULLO • *Institut Cochin, Université Paris Descartes, Paris, France*
- STUART MAUDSLEY • *Receptor Pharmacology Unit, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA*
- DAMIEN MAUREL • *Institut de Génomique Fonctionnelle, University of Montpellier 1 and 2, Montpellier, France*
- VINCENT MESSIER • *Département de Biochimie, Université de Montréal, Montréal, QC, Canada*

- STEPHEN W. MICHNICK • *Département de Biochimie, Université de Montréal, Montréal, QC, Canada*
- RICHARD R. NEUBIG • *Departments of Pharmacology and Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA*
- ALEXANDRA C. NEWTON • *Department of Pharmacology, University of California San Diego, La Jolla, CA, USA*
- SUNG-SOO PARK • *Receptor Pharmacology Unit, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA*
- DARLAINE PÉTRIN • *Department of Pharmacology and Therapeutics, McGill University, Montréal, QC, Canada*
- JEAN-PHILIPPE PIN • *Institut de Génomique Fonctionnelle, University of Montpellier 1 and 2, Montpellier, France*
- GRACIELA PIÑEYRO • *Department of Psychiatry, Faculty of Medicine, University of Montreal, Montreal, QC, Canada; Centre de Recherche du CHU Ste-Justine, Bureau, Montreal, QC, Canada*
- LAURENT PRÉZEAU • *Institut de Génomique Fonctionnelle, University of Montpellier 1 and 2, Montpellier, France*
- STEFANIE L. RITTER • *Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA*
- MÉLANIE ROBITAILLE • *Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada*
- PHILIPPE RONDARD • *Institut de Génomique Fonctionnelle, University of Montpellier 1 and 2, Montpellier, France*
- ALI SALAHPOUR • *Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada*
- SUDHA K. SHENOY • *Departments of Medicine and Cell Biology, Duke University Medical Center, Durham, NC, USA*
- MAY SIMAAN • *Hormones and Cancer Research Unit, Department of Medicine, McGill University Health Center Research Institute, McGill University, Montréal, QC, Canada*
- ROGER K. SUNAHARA • *Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA*
- GISSELLE A. VÉLEZ-RUIZ • *Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI, USA*
- JEAN-PIERRE VILARDAGA • *Laboratory for GPCR Biology, Department of Pharmacology and Chemical Biology, University of Pittsburgh, School of Medicine, Pittsburgh, PA, USA*
- MARK VON ZASTROW • *Departments of Psychiatry and Cellular & Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA*
- LIYUN WANG • *Receptor Pharmacology Unit, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA*
- YU TIAN WANG • *Brain Research Center, University of British Columbia, Vancouver, BC, Canada*
- JOHN K. WESTWICK • *Odyssey Thera Incorporated, San Ramon, CA, USA*
- KEITH V. WOOD • *Promega Corporation, Madison, WI, USA*
- EVAN A. YOST • *Weis Center for Research, Geisinger Clinic, Danville, PA, USA*

- STACY M. YOST • *Weis Center for Research, Geisinger Clinic, Danville, PA, USA*
- GUILLERMO A. YUDOWSKI • *Departments of Psychiatry and Cellular & Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA*
- GERALD W. ZAMPONI • *Department of Physiology and Pharmacology, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada*
- JIN ZHANG • *Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Solomon H. Snyder Department of Neuroscience, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA*
- YU ZHOU • *Receptor Pharmacology Unit, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA*

Contents

<i>Preface</i>	v
<i>Contributors</i>	xi

PART I OVERVIEWS

1 Refining Efficacy: Allosterism and Bias in G Protein-Coupled Receptor Signaling	3
<i>Louis M. Luttrell and Terry P. Kenakin</i>	
2 Imaging-Based Approaches to Understanding G Protein-Coupled Receptor Signalling Complexes	37
<i>Darlaine Pétrin and Terence E. Hébert</i>	
3 Improving Drug Discovery with Contextual Assays and Cellular Systems Analysis	61
<i>John K. Westwick and Jane E. Lamerdin</i>	
4 RGS-Insensitive G α Subunits: Probes of G α Subtype-Selective Signaling and Physiological Functions of RGS Proteins	75
<i>Kuljeet Kaur, Jason M. Kehrl, Raelene A. Charbeneau, and Richard R. Neubig</i>	
5 Bioinformatic Approaches to Metabolic Pathways Analysis	99
<i>Stuart Maudsley, Wayne Chadwick, Liyun Wang, Yu Zhou, Bronwen Martin, and Sung-Soo Park</i>	

PART II RECEPTOR–LIGAND INTERACTIONS

6 Studying Ligand Efficacy at G Protein-Coupled Receptors Using FRET	133
<i>Jean-Pierre Vilardaga</i>	
7 Using BRET to Detect Ligand-Specific Conformational Changes in Preformed Signalling Complexes	149
<i>Nicolas Audet and Graciela Piñeyro</i>	

PART III RECEPTOR–RECEPTOR INTERACTIONS

8 Reconstitution of G Protein-Coupled Receptors into a Model Bilayer System: Reconstituted High-Density Lipoprotein Particles	167
<i>Gisselle A. Vélez-Ruiz and Roger K. Sunahara</i>	
9 Using Quantitative BRET to Assess G Protein-Coupled Receptor Homo- and Heterodimerization	183
<i>Lamia Achour, Maud Kamal, Ralf Jockers, and Stefano Marullo</i>	
10 Cell-Surface Protein–Protein Interaction Analysis with Time-Resolved FRET and Snap-Tag Technologies: Application to G Protein-Coupled Receptor Oligomerization	201
<i>Laëtitia Comps-Agrar, Damien Maurel, Philippe Rondard, Jean-Philippe Pin, Eric Trinquet, and Laurent Prézeau</i>	

11	Analysis of GPCR/Ion Channel Interactions.	215
	<i>Christophe Altier and Gerald W. Zamponi</i>	
PART IV RECEPTOR–EFFECTOR COUPLING		
12	Multicolor BiFC Analysis of G Protein $\beta\gamma$ Complex Formation and Localization	229
	<i>Thomas R. Hynes, Evan A. Yost, Stacy M. Yost, and Catherine H. Berlot</i>	
13	Real-Time BRET Assays to Measure G Protein/Effector Interactions	245
	<i>Darlaine Pétrin, Mélanie Robitaille, and Terence E. Hébert</i>	
14	Luminescent Biosensors for Real-Time Monitoring of Intracellular cAMP.	263
	<i>Brock F. Binkowski, Frank Fan, and Keith V. Wood</i>	
15	Simultaneous Real-Time Imaging of Signal Oscillations Using Multiple Fluorescence-Based Reporters.	273
	<i>Lianne B. Dale and Stephen S.G. Ferguson</i>	
PART V SPATIAL CONTROL OF SIGNAL TRANSDUCTION		
16	Using FRET-Based Reporters to Visualize Subcellular Dynamics of Protein Kinase A Activity	285
	<i>Charlene Depry and Jin Zhang</i>	
17	Genetically Encoded Fluorescent Reporters to Visualize Protein Kinase C Activation in Live Cells	295
	<i>Lisa L. Gallegos and Alexandra C. Newton</i>	
18	Visualizing Receptor Endocytosis and Trafficking	311
	<i>Ali Salabpour and Larry S. Barak</i>	
19	Investigating G Protein-Coupled Receptor Endocytosis and Trafficking by TIR-FM	325
	<i>Guillermo A. Yudowski and Mark von Zastrow</i>	
20	Visualizing G Protein-Coupled Receptor Signalsomes Using Confocal Immunofluorescence Microscopy	333
	<i>Sudha K. Shenoy</i>	
PART VI PROTEIN–PROTEIN INTERACTIONS		
21	Detection and Characterization of Receptor Interactions with PDZ Domains	345
	<i>Stefanie L. Ritter and Randy A. Hall</i>	
22	Tandem Affinity Purification and Identification of Heterotrimeric G Protein-Associated Proteins.	357
	<i>Syed M. Ahmed, Avais M. Daulat, and Stéphane Angers</i>	
23	Study of G Protein-Coupled Receptor/ β -arrestin Interactions Within Endosomes Using FRAP.	371
	<i>Benjamin Aguila, May Simaan, and Stéphane A. Laporte</i>	

24 Disrupting Protein Complexes Using Tat-Tagged Peptide Mimics 381
Shupeng Li, Sheng Chen, Yu Tian Wang, and Fang Liu

25 Protein-Fragment Complementation Assays for Large-Scale Analysis,
 Functional Dissection and Dynamic Studies of Protein–Protein
 Interactions in Living Cells 395
*Stephen W. Michnick, Po Hien Ear, Christian Landry,
 Mohan K. Malleshaiah, and Vincent Messier*

Index 427

Part I

Overviews

Refining Efficacy: Allosterism and Bias in G Protein-Coupled Receptor Signaling

Louis M. Luttrell and Terry P. Kenakin

Abstract

Receptors on the surface of cells function as conduits for information flowing between the external environment and the cell interior. Since signal transduction is based on the physical interaction of receptors with both extracellular ligands and intracellular effectors, ligand binding must produce conformational changes in the receptor that can be transmitted to the intracellular domains accessible to G proteins and other effectors. Classical models of G protein-coupled receptor (GPCR) signaling envision receptor conformations as highly constrained, wherein receptors exist in equilibrium between single “off” and “on” states distinguished by their ability to activate effectors, and ligands act by perturbing this equilibrium. In such models, ligands can be classified based upon two simple parameters; affinity and efficacy, and ligand activity is independent of the assay used to detect the response. However, it is clear that GPCRs assume multiple conformations, any number of which may be capable of interacting with a discrete subset of possible effectors. Both orthosteric ligands, molecules that occupy the natural ligand-binding pocket, and allosteric modulators, small molecules or proteins that contact receptors distant from the site of ligand binding, have the ability to alter the conformational equilibrium of a receptor in ways that affect its signaling output both qualitatively and quantitatively. In this context, efficacy becomes pluridimensional and ligand classification becomes assay dependent. A more complete description of ligand–receptor interaction requires the use of multiplexed assays of receptor activation and screening assays may need to be tailored to detect specific efficacy profiles.

Key words: Agonist, G protein-coupled receptor, Heterotrimeric guanine nucleotide-binding protein, Pharmaceutical chemistry, Pharmacodynamics, Signal transduction

1. Introduction

Most of the basic tenets of receptor pharmacology predate our understanding of the molecular structure of receptors themselves. When Stephenson defined efficacy in 1956, he was studying the acetylcholine-like effects of a series of alkyl-trimethyl

ammonium salts on the contraction of guinea pig ileum (1). In this work, the readout of receptor activation was a relatively simple bioassay. Although the intervening 50 years have seen an explosion in our knowledge of receptor structure and mechanisms of intracellular signaling, even today most drug discovery efforts rely on using a single readout, often in a highly artificial system engineered for high throughput automated screening, as the basis for classifying the effect of ligand binding on receptor activity. Within such systems, where receptor density is constant and activity is measured either as an integrated whole cell or tissue response, e.g., muscle contraction, or a single molecular event, e.g., influx of cytosolic calcium, the relationship between the ligand concentration and receptor activation can be adequately described by two terms; affinity, the equilibrium dissociation constant of the ligand–receptor complex; and the maximal response that can be observed (2, 3), which is a function of efficacy. In this paradigm affinity and efficacy are largely independent functions, i.e., a ligand may have high affinity but low efficacy or vice versa, and ligands are classified as full agonists if they can elicit a maximal response from the system, partial agonists if they can only generate a submaximal response, and antagonists if they lack intrinsic efficacy but interfere with the ability of agonists to evoke a response.

Although these principles provide the framework that has guided signal transduction and drug discovery research for decades, advances in our understanding of the complexity of signal transduction networks and the evolution of technology to measure receptor activation in many dimensions have unambiguously demonstrated that the nature of efficacy is far more complex than originally envisioned, and a more general model is needed to explain the action of ligands on receptors (4). Rather than functioning like simple switches that transition between tightly constrained “off” and “on” states, receptors are highly dynamic proteins capable of adopting a large number of conformational states, some subset of which is capable of coupling to variable sets of downstream effectors. Viewed in this way, it is evident that any ligand, small molecule, or other protein that contacts the receptor in a manner that alters its conformational equilibrium may initiate, attenuate, or even qualitatively change signaling. Orthosteric ligands, allosteric modulators, even other proteins contacting the receptor in the lipid bilayer or on its cytosolic face, all work in essentially the same way. In the sections that follow, we will review the changing concepts of efficacy, their implications for drug development, and the challenges arising from the need to incorporate a more complete characterization of ligand action into experimental and industrial research.

2. Two-State Models of Receptor Activation

When only a single readout of receptor activation is considered, receptors can be described as existing in either an empty “off” state that is silent in the assay or an agonist-bound “on” state that elicits a measurable response. The early model of “induced fit” advanced by Koshland in 1958 to describe enzymatic catalysis, proposed that the interaction between a substrate and amino acid residues within the active site of an enzyme changes the structure of the enzyme so as to bring the catalytic groups into proper alignment (5). In other words, for an enzyme (or receptor) that exists in a preferred low energy “inactive” state and must transition to a higher energy “active” state to function, substrate (or ligand) binding facilitates the transition by contributing energy that makes the “active state” become the new preferred low energy state. The alternative concept of “conformational selection” arises from the Monod–Wyann–Changeux model of allostery, which proposes that proteins exist in spontaneous equilibrium between different conformations and that a molecule that binds to a specific conformation will stabilize it, shifting the conformational population toward that favored state (6). The use of such allosteric models to describe membrane receptor function began in the late 1960s (7, 8). The assumption is that the probability that an unbound receptor will exist in the active state is very low, but that stabilization of this state upon ligand binding drives the equilibrium toward the “on” state by interfering with the transition back to the “off” state.

While molecular simulations favor conformational selection models for the binding of small molecules to proteins (9), selection of a relatively rare pre-existing conformation would thermodynamically resemble conformational induction (10), leaving little need to choose between them in modeling two-state receptor behavior. Structural and biophysical data demonstrate that GPCRs vary widely in their degree of conformational flexibility. One extreme is the visual photoreceptor, rhodopsin, which for many years was the only GPCR for which high-resolution X-ray crystallographic structure was available (11, 12). Given its function, it is not surprising that rhodopsin is completely inactive toward transducin in the dark adapted state, i.e., it has evolved to function as an “on–off” switch. To achieve this, it is tightly constrained in the “off” position by intramolecular interactions between the transmembrane helices, notably an “ionic lock” linking the highly conserved E/DRY sequence found at the cytoplasmic end of TM3 in 70% of class A GPCRs, to the NPxxY motif located in TM6. More recent structures of light-activated rhodopsin and of opsin, the ligand-free form of rhodopsin, bound to a C-terminal fragment of transducin, demonstrate that the upon activation the ionic lock is released, allowing an outward turn of TM6 that exposes the transducin-binding site (13, 14).